Validation of simplified quantitative methods for 3deoxy-3-[18F]fluorothymidine Positron Emission Tomography ([18F]FLT PET) in patients with non-small cell lung cancer treated with tyrosine kinase inhibitor (gefitinib of erlotinib).

Validation of simplified quantitative methods for 3*deoxy-3*-[18F]fluorothymidine Positron Emission Tomography ([18F]FLT PET) in patients with non-small cell lung cancer treated with tyrosine kinase inhibitor (gefitinib of erlotinib). - FLT gefitinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36853

Enrollment

Registered

2012-08-02

Start date

2012-11-19

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer non small cell lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patient age 18 years or older * Histological diagnosis of NSCLC * Active EGFR-TK mutation * Scheduled for treatment with gefitinib or erlotinib * Tumour diameter > 3cm (to minimize partial volume effects) within the chest * Able to remain supine for 90 minutes in the PET-CT scanner * Written informed consent

Exclusion criteria

Exclusion criteria: * Pregnant or lactating patients * Metal implants (e.g. pacemakers) * Body weight > 100 kg

Design outcomes

Primary

Measure	Time frame
The study parameters are the results of the simplified measures and the pharmacokinetic modeling of [18F]FLT PET prior to therapy and during treatment with gefitinib or erlotinib.	—

Secondary

Measure	Time frame
Secondary, nonlinear kinetic filtering will be evaluated and perfusion measured with [15O]H2O PET.	—

Countries

Netherlands

Outcome results